Green Cross to develope anti-cancer genetic therapy.

Published: 2006-10-19 06:56:00

Updated: 2006-10-19 06:56:00

Green Cross has agreed with an exclusive distribution of JX-594, an anti-cancer genetic therapy by the use of recombinant vaccinia virus, with American Generics Biotherapeutics Inc.

JX-594 is a new type of an anti-cancer therapy by combining the GM-CSF granulocyte macrophage colony stimulating...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK